Anti-Factor IX / F9 Polyclonal Antibody for WB, IF-P, ELISA - P00740

Core Product Specifications and Parameters

Biological Background: Factor IX / F9 Function and Localization

• Coagulation factor IX (Christmas factor, plasma thromboplastin component) is a vitamin K-dependent serine protease that plays a critical role in the intrinsic pathway of blood coagulation by converting factor X to its active form (factor Xa) in the presence of Ca²⁺ ions, phospholipids, and factor VIIIa (PubMed:8295821, PubMed:2592373, PubMed:20121197).
  Related references:
  PMID:8295821
  PMID:2592373
  PMID:20121197
• Factor IX is synthesized primarily in the liver and secreted into the blood plasma, where it circulates as an inactive zymogen (PubMed:19846852, PubMed:2592373, PubMed:3857619, PubMed:8295821, PubMed:9169594).
  Related references:
  PMID:19846852
  PMID:2592373
  PMID:3857619
  PMID:8295821
  PMID:9169594
• The protein undergoes extensive post-translational modifications, including gamma-carboxylation of glutamic acid residues, phosphorylation, sulfation, and hydroxylation, which are essential for its calcium-dependent membrane binding and biological activity.
• Alternative splicing generates multiple isoforms of factor IX, contributing to regulatory diversity in coagulation.
• Mutations in the F9 gene cause hemophilia B (Christmas disease), a recessive X-linked bleeding disorder characterized by deficiency in factor IX activity.
• The protein consists of an N-terminal Gla domain, two EGF-like repeats, and a C-terminal serine protease domain, which are essential for calcium binding, protein-protein interactions, and catalytic activity.

Experimental Guidance and Technical Tips

• The immunogen sequence (amino acids 29–192 of human Factor IX) encompasses the Gla domain and EGF-like repeats; therefore, the resulting antibody may recognize both the zymogen and activated forms.
• For Western blotting, a band at approximately 52 kDa is expected, but due to post-translational modifications and potential proteolytic processing, the apparent molecular weight may differ. Validate using appropriate positive controls such as human plasma or liver tissue lysates.
• Positive cross-reactivity with mouse and rat is reported, enabling the antibody’s use in rodent model studies; however, preliminary validation in each experimental system is recommended.
• For ELISA and immunofluorescence (IF-P), consider optimizing antigen retrieval and antibody dilution conditions based on the specific assay format and sample type.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic manufacturers and research institutes with comprehensive IVD raw material solutions. Our Factor IX / F9 polyclonal antibody is part of a broader portfolio that includes validated antibody pairs, optimized monoclonal antibodies, and bulk ancillary reagents for coagulation research and hemostasis assay development. From concept to clinic, CamelBio streamlines your sourcing needs, ensuring consistent supply and technical support tailored to your diagnostic workflow.